{"id":2516,"date":"2015-10-13T22:00:40","date_gmt":"2015-10-14T02:00:40","guid":{"rendered":"http:\/\/cancerawarenessnews.com\/?p=2516"},"modified":"2015-10-16T14:49:50","modified_gmt":"2015-10-16T18:49:50","slug":"90-of-cancer-types-respond-well-to-new-israeli-cancer-vaccine","status":"publish","type":"post","link":"http:\/\/cancerawarenessnews.com\/90-of-cancer-types-respond-well-to-new-israeli-cancer-vaccine\/","title":{"rendered":"90% Of Cancer Types Respond Well To New Israeli Cancer Vaccine"},"content":{"rendered":"

VIDEO: Amazing video on Vaxil BioTherapeutic. Watch video below<\/h3>\n

There\u2019s no doubt that cancer is one of the world\u2019s most vicious diseases. For decades, scientists have been trying to find a cure for cancer, a terminal illness that kills 8 million people worldwide every year. \u00a0READ MORE<\/strong><\/p>\n

\"\"

There\u2019s no doubt that cancer is one of the world\u2019s most vicious diseases. For decades, scientists have been trying to find a cure for cancer, a terminal illness that kills 8 million people worldwide every year.<\/p>\n

BALANCE OF ARTICLE AND AMAZING VIDEO ON NEXT PAGE<\/strong><\/p>\n

\"arrow_down_next_page1\"

<\/p>\n

VIDEO: Amazing video on Vaxil BioTherapeutic.<\/h3>\n

With 14 million new cancer cases diagnosed around the globe every year, according to the World Health Organization, the need for prevention is vital. Now, an Israeli biotechnology company is developing a vaccine for cancer, which is not designed to treat the disease \u2013 but to prevent it from returning.<\/p>\n

Vaxil BioTherapeutics, based in Nes Ziona, Israel, has spent over half a decade developing ImMucin, a prophylactic cancer vaccine, which can trigger a response in about 90 percent of all types of cancer, according to the company.<\/p>\n

Immunotherapy: A hybrid cross between a vaccine and a drug<\/strong>
\n\u201cVaxil is developing a drug to keep the cancer from coming back,\u201d Julian Levy, Vaxil\u2019s CFO, tells NoCamels.com. \u201cWe are trying to harness the natural power of the immune system to fight against cancer by seeking out cancer cells and destroying them.\u201d
\nLevy explains that ImMucin is not a replacement for traditional cancer treatments such as chemotherapy or radiation. Rather, the company is targeting a different stage in the patient\u2019s battle against cancer, specifically the early stages of the detection, as well as during remission. That\u2019s why, unfortunately, the drug won\u2019t be helpful to many cancer patients \u2013 specifically those who are in advanced stages of the disease \u2013 because it requires a relatively healthy body to be fully effective.<\/p>\n

SEE ALSO: Israeli Researchers Create \u2018Trojan Horse\u2019 Of Chemotherapy<\/strong>
\nEven though ImMucin is a vaccine, it is given to people who are already sick, unlike traditional vaccines. So, while ImMucin\u2019s scientific mechanism is one of a vaccine, from the point of view of the patient, it acts exactly like a drug that has physiological effects when introduced to the body.
\n\u201cMany preventative cancer vaccines today are not actual vaccines against cancer,\u201d Levy says. \u201cYoung women can take a vaccine for the HPV virus, which doesn\u2019t combat cancer; it\u2019s a vaccine against a virus that has been proven to lead to a more serious cervical cancer.\u201d<\/p>\n

Training the immune system to attack cancerous cells<\/strong>
\nImMucin works by stimulating a part of the immune system and teaching it to attack certain cells with certain markers that indicate the presence of cancer. When the drug is introduced during an early stage of cancer, the hope is that as a patient\u2019s cancer begins to creep back, the immune system is trained appropriately to know which cells to destroy and which to leave be.
\nThis immune response has been consistent throughout Vaxil\u2019s clinical trials on the vaccine over the past few years. The company ran trials exclusively on Multiple Myeloma patients until January 2014, when it began trials on breast cancer patients.<\/p>\n

Vaxil\u2019s current switch from successful myeloma trials to breast cancer trials would certainly turn some heads in the biotech community. That\u2019s because typically, when a drug has this much success on a certain type of cancer, a company would provide more resources to finish the trials (through Phase III) and get it to market \u2013 it wouldn\u2019t delve into new projects.
\nVaxil\u2019s most recent valuation is just under $3 million. In the US, clinical trials and ongoing research and development can cost hundreds of millions of dollars per drug, and it\u2019s very possible that Vaxil doesn\u2019t have the cash to push ImMucin to the market at this point. However, Levy is confident that ImMucin will be on the market by the end of this decade.<\/p>\n

Vaxil BioTheraputics has promising technology and initial clinical success, especially since ImMucin has the potential to treat 90 percent of cancers found in patients. Certainly, this kind of immunotherapy for an illness previously thought of as incurable, gives hope to millions of patients and their families.
\n